References
- VézinaCKudelskiASehgalSNRapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principleJ Antibiot (Tokyo)197528107217261102508
- MartelRRKliciusJGaletSInhibition of the immune response by rapamycin, a new antifungal antibioticCan J Physiol Pharmacol19775514851843990
- SimamoraPAlvarezJMYalkowskySHSolubilization of rapamycinInt J Pharm20012131–2252911165091
- RoufMABilensoyEVuralIHincalAADetermination of stability of rapamycin following exposure to different conditionsEur J Pharm Sci2007321S46S46
- LuengoJIKonialianALHoltDAStudies on the chemistry of rapamycin: novel transformations under Lewis-acid catalysisTetrahedron Lett1993346991994
- SteffanRJKearneyRMHuDCBase catalyzed degradations of rapamycinTetrahedron Lett1993342336993702
- YohannesDMyersCDDanishefskySJDegradation of rapamycin: synthesis of a rapamycin derived fragment containing the tricarbonyl and triene sectorsTetrahedron Lett1993341320752078
- VasquezEMSirolimus: a new agent for prevention of renal allograft rejectionAm J Health Syst Pharm200057543744810711524
- RosenHAbribatTThe rise and rise of drug deliveryNat Rev Drug Discov20054538138515864267
- ShenLJWuFLLNanomedicines in renal transplant rejection – focus on sirolimusInt J Nanomedicine200721253217722509
- AlemdarAYSadiDMcAlisterVCMendezILiposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic graftsCell Transplant200413326327115191164
- RoufMBilensoyEVuralIHincalAAInclusion complexation of rapamycin with beta-cyclodextrin to improve solubility and stability of the drugEur J Pharm Sci2007321S46S47
- BuechGBertelmannEPleyerUSiebenbrodtIBorchertHHFormulation of sirolimus eye drops and corneal permeation studiesJ Ocul Pharmacol Ther200723329230317593014
- PreethamACSatishCSFormulation of a poorly water-soluble drug sirolimus in solid dispersions to improve dissolutionJ Dispers Sci Technol2011326778783
- KimMSKimJSParkHJChoWKChaKHHwangSJEnhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent processInt J Nanomedicine201162997300922162657
- BalakrishnanPLeeBJOhDHEnhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systemsInt J Pharm20093741–2667219446761
- ShahNHCarvajalMTPatelCIInfeldMHMalickAWSelf-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugsInt J Pharm199410611523
- KimCKChoYJGaoZGPreparation and evaluation of biphenyl dimethyl dicarboxylate microemulsions for oral deliveryJ Control Release2001701–214915511166415
- PrajapatiBGPatelMMConventional and alternative pharmaceutical methods to improve oral bioavailability of lipophilic drugsAsian J Pharm20071118
- SunMSiLZhaiXThe influence of co-solvents on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systemsDrug Dev Ind Pharm201137898699421417621
- HuXLinCChenDSirolimus solid self-microemulsifying pellets: formulation development, characterization and bioavailability evaluationInt J Pharm20124381–212313322850296
- KhooS-MHumberstoneAJPorterCJHEdwardsGACharmanWNFormulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrineInt J Pharm19981671–2155164
- KommuruTRGurleyBKhanMAReddyIKSelf-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessmentInt J Pharm2001212223324611165081
- CraigDQMBarkerSABanningDBoothSWAn investigation into the mechanisms of self-emulsification using particle-size analysis and low-frequency dielectric-spectroscopyInt J Pharm19951141103110
- ConstantinidesPPLipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspectsPharm Res19951211156115728592652
- CarliFChielliniERemediaSRL inventors assigneePharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support WO patent WO 2003-0134212202003
- SwensonESCuratoloWJIntestinal permeability enhancement for proteins, peptides and other polar drugs – mechanisms and potential toxicity 2Adv Drug Deliv Rev1992813992